Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Minor depressive disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Minor depressive disorder. Displaying page 1 of 1.
    EudraCT Number: 2004-004009-10 Sponsor Protocol Number: CL3-20098-046 Start Date*: 2005-06-29
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind inte...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004780-34 Sponsor Protocol Number: A7571001 Start Date*: 2006-04-18
    Sponsor Name:Pfizer Ltd, Sandwich, UK
    Full Title: An eight-week, double-blind, group sequential design, placebo controlled trial to evaluate the safety and efficacy of the co-administration of sertraline and elzasonan (CP-448,187) in outpatients w...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025454 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001172-41 Sponsor Protocol Number: ITI-007-503 Start Date*: 2022-01-13
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) BG (Completed) PL (Completed) SE (Completed) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003038-34 Sponsor Protocol Number: D1002001 Start Date*: 2015-07-07
    Sponsor Name:Sumitomo Dainippon Pharma Co., Ltd.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression
    Medical condition: Bipolar I depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003039-31 Sponsor Protocol Number: D1002002 Start Date*: 2015-08-20
    Sponsor Name:Sumitomo Dainippon Pharma Co., Ltd.
    Full Title: A Long-Term Study of SM-13496 in Patients with Bipolar I Disorder
    Medical condition: Bipolar I depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-004009-93 Sponsor Protocol Number: 12118A Start Date*: 2008-05-20
    Sponsor Name:LUNDBECK ITALIA
    Full Title: Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram
    Medical condition: Depression, anxiety and ICD
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019000-22 Sponsor Protocol Number: 093-050 Start Date*: 2010-11-29
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: Long-Term Eslicarbazepine Acetate Extension Study
    Medical condition: Partial epilepsy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Prematurely Ended) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-002455-25 Sponsor Protocol Number: BIA-2093-304 Start Date*: 2008-09-18
    Sponsor Name:BIAL - Portela & Cª, SA
    Full Title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINI...
    Medical condition: simple partial seizures with no motor symptomatology Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065336 Partial epilepsy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) DE (Completed) GR (Completed) CY (Completed) HU (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-001982-26 Sponsor Protocol Number: OZM-063 Start Date*: 2018-04-26
    Sponsor Name:The Hospital for Sick Children
    Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma...
    Medical condition: Unresectable or progressive low grade glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 15:39:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA